Compare Heron Therapeutics Inc (HRTX) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Atlassian Corporation PLC — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Atlassian Corporation PLC trades at $93.67 (market cap $23.67B). The key difference: Atlassian Corporation PLC is far larger — about 258.8× Heron Therapeutics Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | TEAM | |
|---|---|---|
Market Cap | $91.46M | $23.67B |
Sector | Health | Technology |
52-Week High | $1.96 | $203.00 |
52-Week Low | $0.39 | $57.15 |
Enterprise Value | $189.36M | $23.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
TEAM trades at $96.63, up 3.58% with bullish technical signals and strong analyst support. Revenue growth accelerated to $5.22B in 2025, though net margins remain negative at -4.93%. Recent AI-driven product launches and service collection surpassing $1B ARR highlight innovation momentum. The stock faces resistance near $97 with support at $92.
Outlook remains positive given consensus price target of $114.54 (18.5% upside) and 29 buy ratings. Risks include persistent unprofitability, competitive pressure from Microsoft/ServiceNow, and projected negative cash flow in 2026. Valuation appears reasonable with P/S of 3.96 versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
